| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| XOMA Royalty Corporation | HIL-214 - (NOR-213) | GI.1/GII.4 virus-like particle (VLP) vaccine | Phase 2 | Trial Discontinued | oral | Gastroenterology |
| XOMA Royalty Corporation | RZ402 | Diabetic macular edema (DME) | Phase 2 | Data Released | Oral | Opthalmic |
| XOMA Royalty Corporation | XOMA 213 | Hyperprolactinemia | Phase 2 | Trial Completed | Intravenous | Endocrinology |
| XORTX Therapeutics Inc. | XRx-101 | Acute kidney injury associated with Coronavirus / COVID-19 infection. | Phase 2 | Ongoing | Oral | COVID-19 |
| XORTX Therapeutics Inc. | XRx-008 | Polycystic Kidney Disease (ADPKD) | Phase 2 | Ongoing | Oral | Genetic Disorder |
| XTL Biopharmaceuticals Ltd. | hCDR1 | Systemic Lupus Erythematosus (SLE) | Phase 2 | Subcutaneous | Immunology | |
| Y-mAbs Therapeutics Inc. | DANYELZA (Naxitamab) - (201) | High-risk neuroblastoma (HR-NB) commonly | Phase 2 | Data Released | Intravenous | Oncology |
| Zai Lab Limited | Efgartigimod - (ADHERE) | Chronic inflammatory demyelinating polyneuropathy (CIDP) | BLA Filing | Data Released | Intravenous | Neurology |